Navaratnam, Kate2; Alfirevic, Zarko3; Baker, Philip N3; Gluud, Christian1; Grüttner, Berthold3; Kublickiene, Karolina3; Zeeman, Gerda3; Kenny, Louise C3
1 Copenhagen Trial Unit, Cochranecenteret Rigshospitalet, Rigshospitalet, The Capital Region of Denmark2 Centre for Womens Health Research, University of Liverpool, First Floor, Liverpool Women's Hospital, Crown Street, Liverpool L8 7SS, UK. Kate.Navaratnam@Liverpool.ac.uk.3 unknown
improved pregnancy outcomes via early detection (IMPROvED)
5% of first time pregnancies are complicated by pre-eclampsia, the leading cause of maternal death in Europe. No clinically useful screening test exists; consequentially clinicians are unable to offer targeted surveillance or preventative strategies. IMPROvED Consortium members have pioneered a personalised medicine approach to identifying blood-borne biomarkers through recent technological advancements, involving mapping of the blood metabolome and proteome. The key objective is to develop a sensitive, specific, high-throughput and economically viable early pregnancy screening test for pre-eclampsia.